Best Practices

Best Practices: Nonvalvular Atrial Fibrillation — Profile on an Effective Alternative to Warfarin

A supplement to Cardiology News. This supplement is sponsored by Daiichi Sankyo.

 

Alan K. Jacobson, MD
Jerry Pettis VA Medical Center – Cardiology
Loma Linda, California

This Best Practices supplement to Cardiology News explores challenges associated with atrial fibrillation and a treatment option that is an alternative to warfarin.

This supplement was sponsored and developed by Daiichi Sankyo, Inc. Dr. Jacobson received compensation from Daiichi Sankyo, Inc. for helping to develop the content of this supplement.

Faculty Disclosure: Dr. Jacobson reports that he is a consultant for Alere Corporation; consultant and advisory board member, speaker bureau for Roche Diagnostics; speaker training, speaker bureau, consultant and advisory boards for BMS/Pfizer Alliance; speaker bureau, consultant and advisory boards for Daiichi Sankyo , Inc; and speaker training faculty and speaker bureau consultant and advisory boards for Janssen Pharmaceuticals and Boehringer Ingelheim.

Click to read the supplement

Next Article: